PML and acute promyelocytic leukemia: However, in the remaining 1–2% of cases of morphologically typical APL novel, extremely rare fusion proteins have been identified involving RARα and cryptic gene partners excluding PML. These are often clustered according to their sensitivity to ATRA therapy.